Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ASH 2013 Annual Meeting

7 - 10 Dec 2013
Ernest N. Morial Convention Center, New Orleans, United States of America
Rituximab maintenance therapy and CLL treatment considerations going forward
Prof Ulrich Jäger - Medical University of Vienna, Austria
Rituximab maintenance therapy and CLL treatment considerations going forward ( Prof Ulrich Jäger - Medical University of Vienna, Austria )
1 Jan 2014
Trial results at ASH 2013
Prof Ian Flinn - Sarah Cannon Cancer Center, Nashville, Tennessee, USA
Trial results at ASH 2013 ( Prof Ian Flinn - Sarah Cannon Cancer Center, Nashville, Tennessee, USA )
1 Jan 2014
Meeting the needs of the elderly, unfit CLL patient
Prof Peter Hillmen - The Leeds Teaching Hospitals NHS Trust, Leeds, UK
Meeting the needs of the elderly, unfit CLL patient ( Prof Peter Hillmen - The Leeds Teaching Hospitals NHS Trust, Leeds, UK )
19 Dec 2013
Improving outcomes in chronic lymphocytic leukaemia
Prof John Gribben - Queen Mary University of London, UK and Prof Barbara Eichhor...
Improving outcomes in chronic lymphocytic leukaemia ( Prof John Gribben - Queen Mary University of London, UK and Prof Barbara Eichhorst - University of Cologne, Germany )
19 Dec 2013
Where next for chronic lymphocytic leukaemia in the elderly?
Prof Clemens Wendter, Prof Florence Cymbalista, Prof Anders Österborg
Where next for chronic lymphocytic leukaemia in the elderly? ( Prof Clemens Wendter, Prof Florence Cymbalista, Prof Anders Österborg )
19 Dec 2013
A new trial alters therapy landscape in multiple myeloma
Prof Philippe Moreau - University Hospital Hôtel-Dieu, Nantes, France and Dr Mar...
A new trial alters therapy landscape in multiple myeloma ( Prof Philippe Moreau - University Hospital Hôtel-Dieu, Nantes, France and Dr Maria-Victoria Mateos - University Hospital of Salamanca, Spain )
19 Dec 2013
Where to next for the elderly with acute myeloid leukaemia?
Dr Uwe Platzbecker - University Hospital Dresden, Germany and Prof Gert Ossenkop...
Where to next for the elderly with acute myeloid leukaemia? ( Dr Uwe Platzbecker - University Hospital Dresden, Germany and Prof Gert Ossenkoppele - VU University Medical Center, Amsterdam, Netherlands )
19 Dec 2013
Exciting new developments in the treatment of multicentric Castleman disease
Prof Nikhil Munshi - Harvard Medical School, Massachussets, USA and Dr Raymond W...
Exciting new developments in the treatment of multicentric Castleman disease ( Prof Nikhil Munshi - Harvard Medical School, Massachussets, USA and Dr Raymond Wong - The Chinese University of Hong Kong )
19 Dec 2013
New therapy aspects for myeloid chronic lymphoma
Dr Simon Rule, Prof Martin Dreyling, Prof Olivier Hermine
New therapy aspects for myeloid chronic lymphoma ( Dr Simon Rule, Prof Martin Dreyling, Prof Olivier Hermine )
19 Dec 2013
Encouraging early results with GS-9973 for CLL and NHL
Dr Jeff Sharman- US Oncology, Eugene, Oregon
Encouraging early results with GS-9973 for CLL and NHL ( Dr Jeff Sharman- US Oncology, Eugene, Oregon )
18 Dec 2013
Role of Bcl-2 family in lymphoid malignancies
Prof Andreas Strasser - University of Melbourne, Melbourne, Australia
Role of Bcl-2 family in lymphoid malignancies ( Prof Andreas Strasser - University of Melbourne, Melbourne, Australia )
18 Dec 2013
FLT3-ITD positive acute myeloid leukaemia
Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA
FLT3-ITD positive acute myeloid leukaemia ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )
18 Dec 2013
PI3K-delta inhibitor idelalisib success in CLL
Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA
PI3K-delta inhibitor idelalisib success in CLL ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )
18 Dec 2013
Benefit of lenalidomide and low-dose dexamethasone over standard therapy for mul...
Dr Thierry Facon - Centre Hospitalier Régional Universitaire de Lille, Lille, Fr...
Benefit of lenalidomide and low-dose dexamethasone over standard therapy for multiple myeloma ( Dr Thierry Facon - Centre Hospitalier Régional Universitaire de Lille, Lille, France )
18 Dec 2013
T cell immunotherapy for leukaemia in preclinical setting
Dr Michael Kalos - University of Pennsylvania, Philadelphia, USA
T cell immunotherapy for leukaemia in preclinical setting ( Dr Michael Kalos - University of Pennsylvania, Philadelphia, USA )
17 Dec 2013
Idelalisib and rituximab for previously treated chronic lymphocytic leukaemia (C...
Dr Richard Furman - New York Weill Cornell Medical Center, USA
Idelalisib and rituximab for previously treated chronic lymphocytic leukaemia (CLL) ( Dr Richard Furman - New York Weill Cornell Medical Center, USA )
17 Dec 2013
Gemtuzumab improves event free survival for paediatric acute myeloid leukaemia (...
Dr Alan Gamis - University of Missouri-Kansas City School of Medicine, USA
Gemtuzumab improves event free survival for paediatric acute myeloid leukaemia (AML) ( Dr Alan Gamis - University of Missouri-Kansas City School of Medicine, USA )
17 Dec 2013
Comment: Transplantation and short telomeres increase the risk of cognitive impa...
Dr Jeffrey Miller - University of Minnesota, Minneapolis, USA
Comment: Transplantation and short telomeres increase the risk of cognitive impairment ( Dr Jeffrey Miller - University of Minnesota, Minneapolis, USA )
17 Dec 2013
Equality of access to transplant for ethnic minority patients
Dr Robert Lown - Royal Marsden Hospital, London, UK
Equality of access to transplant for ethnic minority patients ( Dr Robert Lown - Royal Marsden Hospital, London, UK )
17 Dec 2013
New agents in CLL
Dr Jacqueline Barrientos - LIJ Medical Center, New York, USA
New agents in CLL ( Dr Jacqueline Barrientos - LIJ Medical Center, New York, USA )
13 Dec 2013
Full-intensity transplantation and short telomeres increase risk of cognitive im...
Dr Smita Bhatia - City of Hope National Medical Center, Duarte, USA
Full-intensity transplantation and short telomeres increase risk of cognitive impairment after allogeneic haematopoietic cell transplantation ( Dr Smita Bhatia - City of Hope National Medical Center, Duarte, USA )
13 Dec 2013
Targeting tyrosine kinase receptors to tackle CML
Prof Michael Deininger - University of Utah, Salt Lake City, USA
Targeting tyrosine kinase receptors to tackle CML ( Prof Michael Deininger - University of Utah, Salt Lake City, USA )
13 Dec 2013
Chronic lymphocytic leukaemia: A new treatment era is born
Dr John Gribben - Barts Cancer Institute, London, UK
Chronic lymphocytic leukaemia: A new treatment era is born ( Dr John Gribben - Barts Cancer Institute, London, UK )
13 Dec 2013
Chemo-free treatment for acute promyelocytic leukaemia
Dr Luca Mazzarella - European Institute of Oncology, Milan, Italy
Chemo-free treatment for acute promyelocytic leukaemia ( Dr Luca Mazzarella - European Institute of Oncology, Milan, Italy )
13 Dec 2013
Initial phase III results of the first trial in newly diagnosed multiple myeloma
Dr Thierry Facon - Centre Hospitalier Régional Universitaire de Lille, France
Initial phase III results of the first trial in newly diagnosed multiple myeloma ( Dr Thierry Facon - Centre Hospitalier Régional Universitaire de Lille, France )
10 Dec 2013
Lenalidomide promotes CRBN-mediated ubiquitination and degradation of IKZF1 and ...
Dr Jan Krönke - Brigham and Women's Hospital, Boston, USA
Lenalidomide promotes CRBN-mediated ubiquitination and degradation of IKZF1 and IKZF3 ( Dr Jan Krönke - Brigham and Women's Hospital, Boston, USA )
8 Dec 2013
Treating ALL patients with T cells targeted for CD19
Dr Laurence Cooper - MD Anderson Cancer Center, Houston, USA
Treating ALL patients with T cells targeted for CD19 ( Dr Laurence Cooper - MD Anderson Cancer Center, Houston, USA )
8 Dec 2013
Chimeric antigen receptor produces complete responses and long-term persistence ...
Dr. Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA
Chimeric antigen receptor produces complete responses and long-term persistence in children and adults relapsed, refractory ALL ( Dr. Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA )
8 Dec 2013
Long-term functional persistence, B cell aplasia and anti-leukaemia efficacy in ...
Dr Michael Kalos - University of Pennsylvania, Philadelphia, USA
Long-term functional persistence, B cell aplasia and anti-leukaemia efficacy in refractory B cell malignancies ( Dr Michael Kalos - University of Pennsylvania, Philadelphia, USA )
8 Dec 2013
T cells engineered with chimeric antigen receptor targeting CD19 produce signifi...
Dr Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA
T cells engineered with chimeric antigen receptor targeting CD19 produce significant long-term persistence ( Dr Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA )
8 Dec 2013
Removal of alpha/beta T cells and of CD19 B cells in children With acute leuka...
Dr Alice Bertaina - IRCCS Bambino Gesù Children's Hospital, Rome, Italy
Removal of alpha/beta  T cells and of CD19  B cells in children With acute leukaemia ( Dr Alice Bertaina - IRCCS Bambino Gesù Children's Hospital, Rome, Italy )
8 Dec 2013
Transplantation and short telomeres increase the risk of cognitive impairment
Dr Smita Bhatia - City of Hope National Medical Center, Duarte, California
Transplantation and short telomeres increase the risk of cognitive impairment ( Dr Smita Bhatia - City of Hope National Medical Center, Duarte, California )
8 Dec 2013
Study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal...
Dr Raymond Wong - Chinese University of Hong Kong
Study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with multicentric Castleman’s disease ( Dr Raymond Wong - Chinese University of Hong Kong )
8 Dec 2013
In vitro and in vivo assessment of anfibatide, a novel glycoprotein ib antagonis...
Dr Neyu Ni - University of Toronto, Canada
In vitro and in vivo assessment of anfibatide, a novel glycoprotein ib antagonist ( Dr Neyu Ni - University of Toronto, Canada )
8 Dec 2013
Results from the randomised phase III Children’s Oncology Group (COG) trial, AAM...
Dr Alan Gamis - Children’s Mercy Hospital, Kansas City, USA
Results from the randomised phase III Children’s Oncology Group (COG) trial, AAML0531 ( Dr Alan Gamis - Children’s Mercy Hospital, Kansas City, USA )
8 Dec 2013
Final stage II results of the CLL11 trial
Dr Valentin Goede - University of Cologne, Germany
Final stage II results of the CLL11 trial ( Dr Valentin Goede - University of Cologne, Germany )
8 Dec 2013
Donor-derived anti-CD19 chimeric-antigen-receptor-expressing T cells cause regre...
Dr James Kochenderfer - National Cancer Institute, Bethesda, USA
Donor-derived anti-CD19 chimeric-antigen-receptor-expressing T cells cause regression of malignancy ( Dr James Kochenderfer - National Cancer Institute, Bethesda, USA )
7 Dec 2013
Equality of access to transplant for ethnic minority patients
Dr Robert Lown - University College London, UK
Equality of access to transplant for ethnic minority patients ( Dr Robert Lown - University College London, UK )
7 Dec 2013
Effective treatment of chemotherapy-refractory diffuse large B cell lymphoma
Dr James Kochenderfer - National Cancer Institute, Bethesda, USA
Effective treatment of chemotherapy-refractory diffuse large B cell lymphoma ( Dr James Kochenderfer - National Cancer Institute, Bethesda, USA )
7 Dec 2013
Encouraging outcomes in older patients following nonmyeloablative haploidentical...
Dr Yvette Kasamon - Johns Hopkins Kimmel Cancer Center, Baltimore, USA
Encouraging outcomes in older patients following nonmyeloablative haploidentical blood or marrow transplantation ( Dr Yvette Kasamon - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )
7 Dec 2013
Immune reconstitution and preliminary safety analysis of somatic gene therapy
Dr Sung-Yun Pai - Harvard Medical School, Boston, USA
Immune reconstitution and preliminary safety analysis of somatic gene therapy ( Dr Sung-Yun Pai - Harvard Medical School, Boston, USA )
7 Dec 2013